Focal Segmental Glomerulosclerosis Drugs Market Size and Forecast 2024-2033| Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG

Overview and Scope

Focal segmental glomerulosclerosis (FSGS) is a rare type of kidney disease that causes scarring in the kidneys’ filters. Focal segmental glomerulosclerosis (FSGS) drugs refer to medications used to treat and manage the progression of the disease.

Sizing and Forecast

The focal segmental glomerulosclerosis drugs market size has grown strongly in recent years. It will grow from $14.43 billion in 2023 to $15.77 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increasing disease prevalence, growing demand for new treatments, growing interest from pharmaceutical sector, increasing government support

The focal segmental glomerulosclerosis drugs market size is expected to see strong growth in the next few years. It will grow to $22.41 billion in 2028 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to research and development expenditure, rising healthcare expenditure, growing awareness and diagnosis, aging population, government initiatives and funding. Major trends in the forecast period include technological advancements in drug discovery and development, expanding clinical trials pipeline, improved reimbursement for focal segmental glomerulosclerosis drugs treatments, expansion of corporate research facilities.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/focal-segmental-glomerulosclerosis-drugs-global-market-report

Segmentation & Regional Insights

The focal segmental glomerulosclerosis drugs market covered in this report is segmented –

1) By Type: Losmapimod; SHP-627; Sparsentan; TM-5484; Other Types

2) By Treatment: Corticosteroids; Immunosuppressive Drugs; Angiotensin Converting Enzymes (ACE) Inhibitors; A.R. Blockers; Diuretics; Other Treatments

3) By Route of Administration: Oral; Parenteral

4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users

North America was the largest region in the focal segmental glomerulosclerosis drugs market in 2023. The regions covered in the focal segmental glomerulosclerosis (FSGS) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12866&type=smp

Major Driver Impacting Market Growth

The rising prevalence of kidney infections is expected to propel the growth of the focal segmental glomerulosclerosis (FSGS) drugs market going forward. A kidney infection, or pyelonephritis, is a severe type of urinary tract infection (UTI) that affects one or both kidneys. Focal segmental glomerulosclerosis (FSGS) drugs, which are used to treat kidney diseases, offer several benefits in managing the condition and improving kidney function by reducing proteinuria, slowdowns the progression of kidney damage, and helping the patients suffering from kidney diseases with improved quality of life. For instance, in July 2022, according to the Centers for Disease Control and Prevention, a US-based Department of Health and Human Services, around 15%, or 37 million people in the US, were affected by kidney disease. The prevalence among individuals aged 45–64 is 12% and the prevalence among people between 18 and 44 was 6% in 2021. Therefore, the rising prevalence of kidney infections drives the focal segmental glomerulosclerosis (FSGS) market.

Key Industry Players

Major players in the focal segmental glomerulosclerosis drugs market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Fresenius Kabi Ltd., GSK PLC, Medtronic Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., B. Braun Melsungen AG, Hikma Pharmaceuticals PLC, Alexion Pharmaceuticals, Wockhardt, Travere Therapeutics, Aurinia Pharmaceuticals Inc., Omeros Corporation, Dimerix Ltd., Goldfinch Bio.

The focal segmental glomerulosclerosis drugs market report table of contents includes:

1. Executive Summary

2. Focal Segmental Glomerulosclerosis Drugs Market Characteristics

3. Focal Segmental Glomerulosclerosis Drugs Market Trends And Strategies

4. Focal Segmental Glomerulosclerosis Drugs Market – Macro Economic Scenario

5. Global Focal Segmental Glomerulosclerosis Drugs Market Size and Growth

26. South America Focal Segmental Glomerulosclerosis Drugs Market

27. Brazil Focal Segmental Glomerulosclerosis Drugs Market

28. Middle East Focal Segmental Glomerulosclerosis Drugs Market

29. Africa Focal Segmental Glomerulosclerosis Drugs Market

30. Focal Segmental Glomerulosclerosis Drugs Market Competitive Landscape And Company Profiles

Top Major Players: